Streetbeat News

Earnings

GME

GameStop shares are trading lower due to worse-than-expected Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:14 am

MRNA

Moderna's stock is up following the announcement that MRNA-1283 met its Phase 3 trial primary endpoints. Blackstone Life Sciences will invest up to $750 million in Moderna's flu program, with an investor event scheduled today.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:13 am

GME

HOOD

MRK

NCNO

QQQ

SPY

US stocks are poised for a rebound to end the quarter strong, with the S&P 500 Index up over 9% this quarter. Analysts predict a robust April, citing historical trends and potential Fed cuts. Futures are up in premarket trading, with SPY and QQQ ETFs seeing gains. GameStop's stock plunged following its earnings report, while nCino surged. Robinhood announced a new credit card, and Merck's new treatment received FDA approval. Economic data and upcoming earnings reports are also in focus.

Portfolio Pulse from Shanthi Rexaline

March 27, 2024 | 11:13 am

GMDA

Gamida Cell reported a net loss per share of $(0.57) for the fiscal year 2023. As of December 31, 2023, the company holds cash and equivalents worth $46.6 million.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:08 am

KGRN

NIO

PGJ

NIO Inc. (NYSE:NIO) shares fell in premarket trading after the company reduced its Q1 2024 vehicle delivery forecast from 31,000-33,000 to 30,000 units, without updating its revenue target. The company's Q4 vehicle deliveries and revenue also declined. Analysts note a market share decrease, despite an expanded model range. NIO announced a partnership with CATL for battery development. NIO's stock has dropped over 45% in the past year, affecting related ETFs like KGRN and PGJ.

Portfolio Pulse from Nabaparna Bhattacharya

March 27, 2024 | 11:07 am

ALT

Altimmune's stock price declined following the release of disappointing Q4 FY23 earnings and underwhelming lean mass preservation data for pemvidutide.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:07 am

REE

REE Automotive reported a Q4 adjusted EPS of $(3.15), missing the $(2.38) estimate, and sales of $455.00K, missing the $1.35M estimate. This represents a significant decrease in performance compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:05 am

ALT

Altimmune (NASDAQ:ALT) reported Q4 GAAP EPS of $(0.54), missing the $(0.43) estimate, marking a 25.58% increase in losses YoY. Sales rose to $37.00K, up 133.64% from $(110.00K) YoY.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:04 am

GLYC

GlycoMimetics (NASDAQ:GLYC) reported a Q4 EPS loss of $(0.14), surpassing the consensus estimate of $(0.15) by 6.67%. This marks a 26.32% improvement over the previous year's Q4 loss of $(0.19) per share. The company also reported a cash balance of $41.8M.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:02 am

EDAP

Edap TMS (NASDAQ:EDAP) reported Q4 earnings with a loss of $(0.15) per share, missing the $(0.05) estimate by 200%, and a 7.14% decrease from last year. However, their quarterly sales of $21.30M exceeded the $19.66M estimate by 8.34%, marking a 31.55% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 11:02 am